Latest news with #GKOS
Yahoo
3 days ago
- Business
- Yahoo
Those who invested in Glaukos (NYSE:GKOS) three years ago are up 120%
While Glaukos Corporation (NYSE:GKOS) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 21% in the last quarter. In contrast, the return over three years has been impressive. Indeed, the share price is up a very strong 120% in that time. So the recent fall in the share price should be viewed in that context. If the business can perform well for years to come, then the recent drop could be an opportunity. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Because Glaukos made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Over the last three years Glaukos has grown its revenue at 12% annually. That's pretty nice growth. It's fair to say that the market has acknowledged the growth by pushing the share price up 30% per year. It's hard to value pre-profit businesses, but it seems like the market has become a lot more optimistic about this one! It would be worth thinking about when profits will flow, since that milestone will attract more attention. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). Glaukos is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates. Investors in Glaukos had a tough year, with a total loss of 16%, against a market gain of about 13%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 15% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. You might want to assess this data-rich visualization of its earnings, revenue and cash flow. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Those who invested in Glaukos (NYSE:GKOS) three years ago are up 120%
While Glaukos Corporation (NYSE:GKOS) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 21% in the last quarter. In contrast, the return over three years has been impressive. Indeed, the share price is up a very strong 120% in that time. So the recent fall in the share price should be viewed in that context. If the business can perform well for years to come, then the recent drop could be an opportunity. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Because Glaukos made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Over the last three years Glaukos has grown its revenue at 12% annually. That's pretty nice growth. It's fair to say that the market has acknowledged the growth by pushing the share price up 30% per year. It's hard to value pre-profit businesses, but it seems like the market has become a lot more optimistic about this one! It would be worth thinking about when profits will flow, since that milestone will attract more attention. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). Glaukos is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates. Investors in Glaukos had a tough year, with a total loss of 16%, against a market gain of about 13%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 15% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. You might want to assess this data-rich visualization of its earnings, revenue and cash flow. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
San Francisco Chronicle
30-04-2025
- Business
- San Francisco Chronicle
Glaukos: Q1 Earnings Snapshot
ALISO VIEJO, Calif. (AP) — ALISO VIEJO, Calif. (AP) — Glaukos Corp. (GKOS) on Wednesday reported a loss of $18.1 million in its first quarter. On a per-share basis, the Aliso Viejo, California-based company said it had a loss of 32 cents. Losses, adjusted for amortization costs, came to 22 cents per share. The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share. The glaucoma treatments developer posted revenue of $106.7 million in the period, also beating Street forecasts. Nine analysts surveyed by Zacks expected $102.7 million.
Yahoo
30-04-2025
- Business
- Yahoo
Glaukos: Q1 Earnings Snapshot
ALISO VIEJO, Calif. (AP) — ALISO VIEJO, Calif. (AP) — Glaukos Corp. (GKOS) on Wednesday reported a loss of $18.1 million in its first quarter. On a per-share basis, the Aliso Viejo, California-based company said it had a loss of 32 cents. Losses, adjusted for amortization costs, came to 22 cents per share. The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share. The glaucoma treatments developer posted revenue of $106.7 million in the period, also beating Street forecasts. Nine analysts surveyed by Zacks expected $102.7 million. Glaukos expects full-year revenue in the range of $475 million to $485 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on GKOS at Sign in to access your portfolio
